Business context and reporting period
This is Celsion Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 15, 2020. Although the request identifies Imunon, the filing names Celsion Corporation as the registrant (ticker CLSN). Celsion was a clinical-stage oncology drug developer, with ThermoDox in a Phase III liver-cancer trial and GEN-1 in development for ovarian cancer.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 or comparison |
|---|---|---|
| Technology development and licensing revenue | $125,000 | $125,000 |
| Research and development expense | $3.05 million | $2.77 million |
| General and administrative expense | $1.84 million | $2.22 million |
| Total operating expenses | $4.89 million | $4.99 million |
| Loss from operations | $4.77 million | $4.86 million |
| Net loss | $5.06 million | $2.37 million |
| Basic and diluted loss per share | $0.20 | $0.12 |
| Net cash used in operating activities | $4.98 million | $5.54 million |
| Cash and cash equivalents at period-end | $5.75 million | $3.58 million |
Revenue was licensing-related, not product revenue. Operating expenses exceeded revenue substantially; a profit margin is not meaningful for this development-stage company. Net loss increased largely because Q1 2019 included a $3.13 million non-cash gain from revaluing the earn-out liability, whereas Q1 2020 recorded a $41,000 non-cash charge. Operating loss improved by about $95,000 year over year.
At March 31, current assets were $18.88 million and current liabilities $7.43 million, giving working capital of $11.45 million, versus $8.34 million at December 31, 2019. Cash, short-term investments, accrued investment interest and the New Jersey NOL-sale receivable totaled about $17.5 million. The company reported $9.90 million of note payable, net of financing costs, and $1.44 million of operating lease liabilities. Operating cash use was partly offset by $5.79 million of net equity proceeds; cash declined by $1.13 million during the quarter.
Material changes and financing
- R&D expense rose 10.3% to $3.05 million, including increased GEN-1/OVATION 2 development spending; OPTIMA Study costs declined year over year.
- G&A expense fell 17.0% to $1.84 million, primarily from lower personnel, stock-compensation and professional-fee costs.
- The February 2020 registered offering raised approximately $4.8 million gross from 4.57 million shares and included warrants; the company exchanged the original warrants for warrants covering 3.2 million shares at a higher $1.24 exercise price. It also sold shares under its Aspire facility before terminating that agreement in March.
- In April, the company received approximately $1.8 million from selling New Jersey net operating losses. It received a $632,220 Paycheck Protection Program loan but returned the proceeds in full on May 13, 2020. On that date, Horizon agreed to defer the first two principal payments, totaling $833,333, due in August and September 2020.
- Management said available resources, future NOL sales and remaining capacity under the JonesTrading equity facility were expected to fund operations through mid-2021. This is a forecast, not a guarantee; management also said additional capital may be needed sooner or in greater amounts than anticipated.
Outlook, risks and unusual items
- The OPTIMA Phase III trial had reached its 158-death threshold for the second planned interim analysis, announced April 15. At filing, the independent monitoring committee was expected to meet in July 2020; the filing does not report that analysis’s outcome. The earlier 128-event review recommended continuing the trial, but company discussion of blinded data and historical subgroup results should not be treated as proof of efficacy.
- For GEN-1, the company reported preliminary OVATION 2 surgical-resection results and an orphan-drug recommendation from the EMA committee. These are early-stage findings and do not establish clinical benefit or regulatory approval.
- COVID-19 had not materially affected Q1 results according to the company, but could disrupt clinical enrollment and operations, supply chains, regulatory timelines and access to financing. The magnitude was not determinable.
- The company expected operating losses to continue and had approximately $296 million of cumulative losses. Development, trial, regulatory and commercialization outcomes remain uncertain; further equity financing could dilute shareholders.
- A shareholder derivative and putative class action alleged fiduciary-duty breaches related to approval of the 2018 Stock Incentive Plan. The matter was at an early stage and its outcome was not determinable.
- The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing entity: this 10-Q is for Celsion Corporation, not a registrant named Imunon.
- Check the outcome and timing of the OPTIMA second interim analysis, and distinguish independent committee conclusions from company-reported historical or blinded comparisons.
- Assess cash burn, the mid-2021 runway assumption, available equity-facility capacity and potential dilution, including outstanding warrants and options.
- Review the Horizon loan terms and deferred payments, the completed NOL sale proceeds, and the return of the PPP loan when evaluating liquidity.
- Monitor COVID-19 effects on trial conduct and supply, the shareholder litigation, and any impairment or valuation updates for acquired intangible assets and goodwill.